Cumberland Pharmaceuticals (CPIX) Proxy filing summary

Executive summary

• Shareholders are asked to approve the sale of all FDA-approved commercial products and related assets to Apotex for $100 million in cash, with the company retaining its ifetroban product candidates and early-stage subsidiary CET.

• The board unanimously recommends voting in favor of the transaction, which is structured as an asset purchase and may be deemed a sale of substantially all assets under Tennessee law.

• The transaction is expected to close in Q2 or Q3 2026, subject to shareholder approval and other closing conditions.

• Proceeds will be used to maximize the value of retained programs and for working capital; no dividend distribution is currently planned.

• If not approved, the company will continue operating as before but will not receive the anticipated benefits of the transaction.

Voting matters and shareholder proposals

• Proposal 1: Approve the sale of FDA-approved products and related assets to Apotex.

• Proposal 2: Authorize the board to adjourn/postpone the meeting if more time is needed to solicit votes.

• Shareholders of record as of May 12, 2026, are entitled to vote; each share equals one vote.

• Approval of Proposal 1 requires a majority of all shares entitled to vote; Proposal 2 requires more votes for than against.

• No appraisal rights are available to shareholders in connection with this transaction.

Board of directors and corporate governance

• The board consists of seven members and formed a special committee to evaluate strategic alternatives.

• Directors and executive officers collectively hold approximately 41% of outstanding shares and have entered into voting and support agreements to vote in favor of the transaction.

• The board's decision followed a thorough review of strategic alternatives and negotiations with multiple parties.